Philippe Chanson

发表

Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency.

G. Conway, M. Zacharin, M. Tauber, 2009, European journal of endocrinology.

A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.

M. Jaffrain-Rea, G. Stalla, A. Colao, 2017, European journal of endocrinology.

[Aggressive and resistant-to-treatment pituitary tumors].

P. Chanson, T. Cuny, T. Cuny, 2013, Annales d'endocrinologie.

Cabergoline for Cushing's disease: a large retrospective multicenter study.

M. Haissaguerre, B. Delemer, D. Maiter, 2017, European journal of endocrinology.

Diagnosis and treatment of acromegaly complications

P. Chanson, F. Casanueva, M. Vance, 2003, Journal of endocrinological investigation.

Drug treatment of hyperprolactinemia.

P. Chanson, B. Estour, F. Borson‐Chazot, 2007, Annales d'endocrinologie.

French consensus on the management of acromegaly.

P. Chanson, A. Tabarin, J. Bertherat, 2009, Annales d'endocrinologie.

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.

P. Chanson, D. Dewailly, I. Morange, 1994, The Journal of clinical endocrinology and metabolism.

Variable growth hormone profiles following withdrawal of long-term 30mg slow-release lanreotide treatment in acromegalic patients: clinical implications.

P. Chanson, A. Tabarin, P. Caron, 2000, European journal of endocrinology.

Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN 1. GENEM 1. Groupe d'Etude des Néoplasies Endocriniennes Multiples de type 1.

P. Chanson, G. Cadiot, A. Murat, 1997, Hormone research.

GH deficiency in adults: an epidemiological approach.

G. Sassolas, P. Chanson, J. Bringer, 1999, European journal of endocrinology.

Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumour size in bromocriptine‐resistant prolactinomas

P. Chanson, A. Lavoinne, L. Duranteau, 1991, Clinical endocrinology.

Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.

P. Chanson, P. Caron, C. Teutsch, 2001, The Journal of clinical endocrinology and metabolism.